Rhythm Pharmaceuticals Receives Positive Chmp Opinion for ▼Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old With Bardet Biedl Syndrome or Pomc, Pcsk1, or Lepr Deficiency
rhythm pharmaceuticals因治療Bardet Biedl綜合症或Pomc、Pcsk1或Lepr缺陷的2至6歲患者的肥胖和控制飢餓而獲得▼Imcivree®（Setmelanotide）獲得積極的歐洲藥品管理局意見。